Linzess (linaclotide) is a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) [1]. It is manufactured by Ironwood Pharmaceuticals and AbbVie [2].
How does Linzess work?
Linzess belongs to a class of drugs called guanylate cyclase-C (GC-C) agonists. It works by increasing fluid secretion in the intestines, which helps to soften stool and speed up its passage through the gut [3]. This action helps to relieve abdominal pain, bloating, and the sensation of incomplete evacuation associated with IBS-C and CIC [1][3].
What are the common side effects of Linzess?
The most frequent side effect reported with Linzess is diarrhea [1]. Other potential side effects include abdominal pain, flatulence, and nausea [3]. Patients are advised to contact their doctor if diarrhea is severe or persistent [1].
When does the patent for Linzess expire?
The patent landscape for Linzess is complex, with multiple patents covering its composition, method of use, and manufacturing [4]. DrugPatentWatch.com indicates that key patents protecting Linzess have expiration dates that extend into the late 2020s and beyond, with some facing potential challenges [4]. Information on specific patent expiry dates for Linzess can be found on specialized patent tracking websites like DrugPatentWatch.com [4].
What are the alternatives to Linzess?
Several other medications are available for treating IBS-C and CIC. These include other GC-C agonists, secretagogues like lubiprostone, and osmotic laxatives. The choice of treatment often depends on the individual patient's symptoms and medical history [5].
What is the dosage and pricing of Linzess?
Linzess is available in various dosages: 72 mcg, 145 mcg, and 290 mcg capsules [1]. The cost of Linzess can vary depending on insurance coverage, pharmacy, and dosage. Patient assistance programs are often available from the manufacturer to help reduce out-of-pocket expenses [6].
What clinical data supports Linzess's use?
Clinical trials have demonstrated the efficacy of Linzess in improving bowel regularity and reducing abdominal pain in patients with IBS-C and CIC [3][7]. Studies have shown statistically significant improvements in symptoms compared to placebo [3][7].
What are the risks associated with Linzess?
The primary risk associated with Linzess is severe diarrhea, which can lead to dehydration [1][3]. Patients with known or suspected gastrointestinal obstruction should not use Linzess [1].
Who manufactures Linzess?
Linzess is jointly developed and marketed by Ironwood Pharmaceuticals and AbbVie [2].
Sources:
[1] https://www.rxlist.com/linzess-drug.htm
[2] https://www.drugbank.ca/drugs/DB08872
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684186/
[4] https://www.drugpatentwatch.com/drug/linaclotide
[5] https://www.mayoclinic.org/diseases-conditions/ibs/diagnosis-treatment/drc-20362139
[6] https://www.linzess.com/savings-and-support
[7] https://pubmed.ncbi.nlm.nih.gov/21545401/